Table 2.
CART1 and CART2 treatment characteristics
| Characteristic | Overall, N = 44 | ALL, N = 14 | CLL, N = 9 | NHL, N = 21 |
|---|---|---|---|---|
| Pre-CART1 lymphodepletion | ||||
| Cy-Flu | 34 (77) | 11 (79) | 7 (78) | 16 (76) |
| Non-Cy-Flu | 10 (23) | 3 (21 | 2 (22) | 5 (24) |
| CART1 dose | ||||
| 2 × 105 CAR T cells/kg | 16 (36) | 12 (86) | 2 (22 | 2 (9.5) |
| 2 × 106 CAR T cells/kg | 26 (59) | 2 (14) | 7 (78) | 17 (81) |
| 2 × 107 CAR T cells/kg | 2 (4.5) | 0 (0) | 0 (0) | 2 (9.5) |
| Pre-CART2 lymphodepletion | ||||
| Cy-Flu | 38 (86) | 12 (86) | 9 (100) | 17 (81) |
| Non-Cy-Flu | 2 (4.5) | 0 (0) | 0 (0) | 2 (9.5) |
| No lymphodepletion | 4 (9.5) | 2 (14) | 0 (0) | 2 (9.5) |
| CART2 dose | ||||
| 2 × 106 CAR T cells/kg | 22 (50) | 14 (100) | 3 (33) | 5 (24) |
| 2 × 107 CAR T cells/kg | 22 (50) | 0 (0) | 6 (67) | 16 (76) |
| Dose augmentation (CART2 > CART1 dose) | 36 (82) | 12 (86) | 8 (89) | 16 (76) |
| Doses for CART1 and CART2 | ||||
| 2 × 105 then 2 × 106 CAR T cells/kg | 16 (36) | 12 (86) | 2 (22) | 2 (9.5) |
| 2 × 106 CAR T cells/kg for CART1 and CART2 | 6 (14) | 2 (14) | 1 (11) | 3 (14) |
| 2 × 106 then 2 × 107 CAR T cells/kg | 20 (45) | 0 (0) | 6 (67) | 14 (67) |
| 2 × 107 CAR T cells/kg for CART1 and CART2 | 2 (4.5) | 0 (0) | 0 (0) | 2 (9.5) |
| Lymphodepletion changes from CART1 to CART2 | ||||
| Cy-Flu pre-CART1 and pre-CART2 | 32 (73) | 9 (64) | 7 (78) | 16 (76) |
| Cy-Flu pre-CART1; non-Cy-Flu pre-CART2 | 2 (4.5) | 2 (14) | 0 (0) | 0 (0) |
| Non-Cy-Flu pre-CART1; Cy-Flu pre-CART2 | 6 (14) | 3 (21) | 2 (22) | 1 (4.8) |
| Non-Cy-Flu pre-CART1 and pre-CART2 | 4 (9.1) | 0 (0) | 0 (0) | 4 (19) |
Data presented as n (%).